Stockscreener 앱 받기
2.18
3.81%
0.08
시간 외 거래:
2.16
-0.02
-0.92%
Biovie Inc 주식(BIVI)의 최신 뉴스
BioVie Inc Warrant 2025-01.06.30 on BioVie Financial Disclosures & SEC Filings - TradingView
Enterprise value to EBIT forward of BioVie Inc. – NASDAQ:BIVI - TradingView
BioVie Inc. Class A Financial Disclosures & SEC Filings - TradingView
[EFFECT] BIOVIE INC. SEC Filing - Stock Titan
BioVie Inc. Class A Actuals & Estimates (NASDAQ:BIVI) - TradingView
BioVie | 4: Statement of changes in beneficial ownership of securities-Officer DO CUONG V - Moomoo
BIVI Forecast — Price Target — Prediction for 2027 - TradingView
BioVie Inc (BIVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biovie Files To Offer Up To $300 Million In SecuritiesSEC Filing - TradingView
BioVie (NASDAQ: BIVI) files $300M shelf registration to sell securities - Stock Titan
BioVie Inc (BIVI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BioVie Inc (BIVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioVie Inc (BIVI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioVie Inc (BIVI) Institutional Confidence - TradingKey
BioVie Inc (BIVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
BioVie Inc (BIVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BioVie Inc (BIVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioVie Inc (BIVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BIVI Q1 2026 Earnings: EPS Beat Driven by Lower-than-Expected Operating ExpensesAdjusted Earnings Analysis - newsline.com
BIVI Q1 2026 Earnings: Narrower Loss Than Expected as Pipeline Progress ContinuesEnergy Earnings Report - newsline.com
BIVI Q1 2026 Earnings: EPS Beat Amid Clinical Progress; Stock DeclinesShare Repurchase Impact - newsline.com
Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareh - GuruFocus
Law firm investigates BioVie officers for possible breach of duties to shareholders - Pluang
BioVie Inc. (BIVI) Q1 2026 Earnings: EPS Surpasses Estimates Despite Ongoing Revenue VoidEarnings Call Highlights - newsline.com
BIVI Q1 2026 Earnings: Narrower-Than-Expected Loss but Stock Declines on No Revenue StreamTrough Earnings Signal - newsline.com
Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Barchart.com
Is BioVie's Bezisterim Poised for a Breakthrough in Neurodegenerative Diseases - Kavout | AI
BIVI: Imminent clinical data for Parkinson's and long COVID could unlock major commercial opportunities - TradingView
BioVie Deadline Alert - TMX Newsfile
BioVie Inc. Warrant (BIVIW) Holds Steady Near Support – Waiting for a CatalystProfitability Factor - newsline.com
BIVI Q1 2026 Earnings: Narrower Loss than Expected as Clinical Pipeline AdvancesTrough Earnings Signal - newsline.com
BioVie: Long COVID trial fully enrolled – ICYMI - Yahoo Finance
Foremost Clean Energy and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
BioVie Inc. (BIVI) Hovers Near Key Support Levels as Stock Remains FlatAdvance Decline Line - The Legal Advocate
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2 - Weekly Voice
BioVie to highlight neuro and liver disease programs in June 2 investor webinar - Proactive financial news
BioVie Inc. (BIVI) Declines 5.26%, Testing Key Support Near $1.37Dealer Gamma - The Legal Advocate
BioVie Inc. (BIVI) Declines 5.26%, Testing Critical Support Near $1.37BPI Bear Confirmed - The Legal Advocate
BIVI Q1 2026 Earnings: EPS Beats Estimates Despite No Revenue, Stock DropsEstimate Accuracy - The Legal Advocate
Small cap wrap: First Phosphate, Miivo Holdings, 1911 Gold, BioVie… - Proactive financial news
BioVie completes enrollment in Long COVID trial as need for treatments grows - Proactive financial news
BioVie Inc. (BIVI) Faces Selling Pressure as Shares Slide 5.9%Momentum Trade - The Legal Advocate
BioVie (BIVI) Completes Enrollment for Phase 2 Trial of Bezister - GuruFocus
BioVie completes enrollment in Phase 2 Long COVID trial - Yahoo! Finance Canada
BioVie completes enrollment in Long COVID treatment trial - Investing.com
BioVie completes enrollment in Long COVID treatment trial By Investing.com - Investing.com Nigeria
BIVIBioVie Inc Stock Price and Quote - Finviz
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID - The Manila Times
1.18%
2.48%
자본화:
|
볼륨(24시간):